Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL612679 Target Snapshot

Respiratory syncytial virus · ORGANISM · Respiratory syncytial virus

Back to Search Search this target Browse approvals Evidence Card
2,781Compounds
464Assays
5Approved Drugs
2,264.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Respiratory syncytial virus as ChEMBL target CHEMBL612679. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Respiratory syncytial virus
ORGANISM · Respiratory syncytial virus
As of 2026-09-14
ChEMBL target ID
CHEMBL612679
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Respiratory syncytial virus still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameRespiratory syncytial virus
Target TypeORGANISM
OrganismRespiratory syncytial virus
ChEMBL ↗ NCBI Taxonomy ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelRespiratory syncytial virus
UniProt AccessionN/A

Respiratory syncytial virus

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Respiratory syncytial virus.

Review nameRespiratory syncytial virus
OrganismRespiratory syncytial virus
Clinical Profile

Clinical Phase Distribution

5
Approved
1
Phase III
7
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC50285.0
EC501,979.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4449209 10.62 EC50 0.024 Preclinical
CHEMBL408963 10.5 EC50 0.03162 Preclinical
CHEMBL272218 10.0 EC50 0.1 Preclinical
CHEMBL3410450 10.0 EC50 0.1 Clinical
CHEMBL5620198 9.89 EC50 0.13 Preclinical
CHEMBL4528752 9.82 EC50 0.15 Preclinical
CHEMBL242456 9.8 EC50 0.16 Preclinical
CHEMBL4293427 9.74 IC50 0.18 Preclinical
CHEMBL4520739 9.7 EC50 0.2 Preclinical
CHEMBL5619723 9.66 EC50 0.22 Preclinical
Distribution

pChEMBL Value Distribution

171
5.0
117
5.5
163
6.0
167
6.5
124
7.0
113
7.5
94
8.0
47
8.5
25
9.0
15
9.5
pChEMBL
Approved Drugs

Approved Drugs

REMDESIVIR
CHEMBL4065616
Approved 2020
Properties Compare Identifier
MYCOPHENOLIC ACID
CHEMBL866
Approved 2004
Properties Compare Identifier
RIBAVIRIN
CHEMBL1643
Approved 1985
Properties Compare Identifier
PYRIMETHAMINE
CHEMBL36
Approved 1953
Properties Compare Identifier
Assay Landscape

Assay Landscape

464
Total Assays
1,040
Tested Compounds
1
Assay Types
Functional — 464 assays, 1,040 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 438 993 6.4
cell-based format 26 47 5.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine